Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
02 Maio 2023 - 9:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage
biotechnology company developing novel LAG-3 immunotherapies for
cancer and autoimmune disease, today announces a Key Opinion Leader
(KOL) event will be hosted by Ladenburg Thalmann & Co, Inc., on
Tuesday, May 9, 2023, from 11:30 AM – 1:00 PM ET.
The “Deep Dive into Efti Development in NSCLC
and HNSCC Landscapes” discussion will be led by Ladenburg Thalmann
biotech analyst Ahu Demir, Ph.D., and
feature Martin Forster, M.D., Ph.D.,
of the University College London (UCL) Cancer Institute
and UCL Hospital NHS Foundation, London, UK, and Wade T. Iams,
M.D., MSCI, Assistant Professor of Medicine in the Department of
Medicine’s Division of Hematology and Oncology, and Director of
Thoracic Clinical Trials, at Vanderbilt University Medical Center
(VUMC).
To register for the KOL Event, please visit:
Webinar Registration
KOL Biographies:Dr. Martin Forster specialises
in thoracic and head and neck cancers and has a particular interest
in drug development and in using the increasing understanding of
cancer biology to design studies that distinguish patient
populations most likely to gain benefit from new drugs and new drug
combinations. He is a core member of the lung and head & neck
cancer teams at UCL and runs a research-based practice, being
principal investigator or chief investigator for over 70 early and
late-phase clinical trials, from first-in-human to registration
Phase III trials. He collaborates broadly with national and
international groups involved in translational research and is
joint lead for the clinical trials theme of the Cancer Research UK
Lung Cancer Centre of Excellence and chairs the NIHR Head and Neck
Research Group.
Dr. Wade Iams is a translational researcher
specializing in thoracic malignancies. His research focuses on
discovering and validating novel blood biomarkers that can be used
to better monitor lung cancer patients and identifying genetic
factors that may play a role in the development of lung cancer. Dr.
Iams also helps conduct clinical trials at Vanderbilt for patients
with thoracic malignancies and with a special focus on new
immuno-oncology strategies in patients with solid tumors. His
research has been funded by an American Society of Clinical
Oncology/Conquer Cancer Foundation Young Investigator Award.
About Eftilagimod Alpha (Efti)
Efti is Immutep’s proprietary soluble LAG-3
protein and MHC Class II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a first-in-class
antigen presenting cell (APC) activator, efti binds to MHC (major
histocompatibility complex) Class II molecules on APC leading to
activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper
T cells, dendritic cells, NK cells, and monocytes. It also
upregulates the expression of key biological molecules like IFN-ƴ
and CXCL10 that further boost the immune system’s ability to fight
cancer.
Efti is under evaluation for a variety of solid
tumours including non-small cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its
favourable safety profile enables various combinations, including
with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has
received Fast Track Designation in 1st line HNSCC and in 1st line
NSCLC from the United States Food and Drug Administration
(FDA).
About
ImmutepImmutep is a clinical stage biotechnology
company developing novel LAG-3 immunotherapy for cancer and
autoimmune disease. We are pioneers in the understanding and
advancement of therapeutics related to Lymphocyte Activation Gene-3
(LAG-3), and our diversified product portfolio harnesses its unique
ability to stimulate or suppress the immune response. Immutep is
dedicated to leveraging its expertise to bring innovative treatment
options to patients in need and to maximise value for shareholders.
For more information, please visit www.immutep.com.
Australian
Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406
759 268; cstrong@citadelmagnus.com
U.S. Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024